← Back to Search

Cardiac MRI for Tricuspid Regurgitation

N/A

Waitlist Available

Led By Mohamad Alkhouli, MD

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

No Placebo-Only Group

Summary

This trial assesses the severity of tricuspid regurgitation with cardiac MRI.

Who is the study for?

This trial is for individuals with moderate or severe tricuspid regurgitation, which is when the heart's tricuspid valve doesn't close properly. Participants must not have a pacemaker/defibrillator that interferes with MRI, any prior tricuspid valve replacements, planned surgery on the tricuspid valve, or primary liver disease.

What is being tested?

The study aims to evaluate how well cardiac magnetic resonance imaging (MRI) can determine the severity of tricuspid regurgitation in patients' hearts.

What are the potential side effects?

Cardiac MRI is generally safe; however, some may experience discomfort from lying still during the procedure. There are no significant side effects associated directly with this non-invasive imaging technique.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Incidence of Severity of tricuspid regurgitation by cardiac magnetic resonance imaging

Secondary study objectives

Correlation between severity of Tricuspid regurgitation by cardiac magnetic resonance imaging vs. elastography

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Moderate or severe tricuspid regurgitationExperimental Treatment1 Intervention

40 patients with moderate or more TR on echocardiography will undergo CMR/MRE with contrast to assess TR severity, and the associated extra-valvular cardiac and liver abnormalities. Patients will continue their clinical management by their primary physicians as per the standards of care. 1-year follow up will be conducted via phone to inquire about patient's vital status (dead/alive), symptoms and hospitalizations.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cardiac Magnetic Resonance

2018

N/A

~150

Do I qualify?Apply below to find out